Bast RC Jr et al. 2000 update of recommendations
for the use of tumor markers in breast and colorectal cancer:
Clinical practice guidelines of the American Society of
Clinical Oncology. J Clin Oncol 2001;19(6):1865-78.
Abstract.
Clinton SR et al. A comparative study of four serological
tumor markers for the detection of breast cancer. Biomed
Sci Instrum 2003;39:408-14. Abstract.
Duffy MJ. Biochemical markers in breast cancer:
Which ones are clinically useful? Clin Biochem
2001;34(5):347-52. Abstract.
Gion M et al. CA27.29: A valuable marker for breast
cancer management. A confirmatory multicentric study on
603 cases. Eur J Cancer 2001;37(3):355-63. Abstract.
Gion M et al. Tumor markers in breast cancer monitoring
should be scheduled according to initial stage and follow-up
time: A prospective study on 859 patients. Cancer
J 2001;7(3):181-90. Abstract.
Guadagni F et al. A re-evaluation of carcinoembryonic
antigen (CEA) as a serum marker for breast cancer: A prospective
longitudinal study. Clin Cancer Res 2001;7(8):2357-62.
Abstract.
Jager W et al. Serial CEA and CA 15-3 measurements
during follow-up of breast cancer patients. Anticancer
Res 2000;20(6D):5179-82. Abstract.
Kurebayashi J et al. Significance of Serum Carcinoembryonic
Antigen and CA 15-3 in monitoring advanced breast cancer
patients treated with systemic therapy: A large-scale retrospective
study. Breast Cancer 2003;10(1):38-44. Abstract.
Lauro S et al. Comparison of CEA, MCA, CA 15-3
and CA 27-29 in follow-up and monitoring therapeutic response
in breast cancer patients. Anticancer Res 1999;19(4C):3511-5.
Abstract.
Lufter D et al. A comparison of bone-related biomarkers
and CA27.29 to assess response to treatment of osseous
metastatic breast cancer. Anticancer Res 2000;20(6D):5099-105.
Abstract.
Robertson JF et al. The objective measurement of
remission and progression in metastatic breast cancer by
use of serum tumour markers. European Group for Serum Tumour
Markers in Breast Cancer. Eur J Cancer 1999;35(1):47-53.
Abstract.
Smith TJ et al. American Society of Clinical Oncology
1998 update of recommended breast cancer surveillance guidelines. J
Clin Oncol 1999;17(3):1080-2. Abstract.
Sutterlin M et al. Predictive value of CEA and
CA 15-3 in the follow up of invasive breast cancer. Anticancer
Res 1999;19(4A):2567-70. Abstract.
Valenzuela P et al. The contribution of the CEA
marker to CA 15.3 in the follow-up of breast cancer. Eur
J Gynaecol Oncol 2003;24(1):60-2. Abstract.
|
